<DOC>
	<DOCNO>NCT02588950</DOCNO>
	<brief_summary>This purpose two-part study measure much study drug get blood stream long take body get rid . In Part A , participant receive two treatment , single dose continuous dose U-500R insulin , administer skin . Participants complete Part A continue Part B assign 1 2 treatment U-500R insulin , inject either twice three time daily skin 5-10 day . This study last 7-14 week include initial screening follow .</brief_summary>
	<brief_title>A Study U-500 Insulin ( LY041001 ) Participants With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Males female type 2 diabetes mellitus ( T2DM ) Are current user U100 , U200 and/or U300 insulin/analog , basal , premixed and/or basal/bolus deliver injection device ( pens and/or syringe/vial exclude continuous subcutaneous infusion ( CSII ) /insulin pump use precede 3 month ) , take total daily dose ( TDD ) great equal ( ≥ ) 150 unit ( U ) least one dose great ( &gt; ) 100 U part multiple daily injection ( MDI ) regimen TDD le equal ( ≤ ) 3.0 unit per kilogram ( U/kg ) Concomitant antihyperglycemic agent ( ) ( AHA ) therapy may include : metformin ( MET ) , dipeptidyl peptidase 4 inhibitor , pioglitazone ( dose ≤30 milligram per day ( mg/day ) ) , glucagon like peptide ( GLP ) 1 receptor agonist , sodiumglucose cotransporter2 ( SGLT2 ) inhibitor , except combination GLP1 receptor agonists Participant 's antihyperglycemic agent ( AHA ) therapy must stable ≥3 month ( except weekly GLP1 receptor agonist must stable ≥4 month ) Have hemoglobin A1c ( HbA1c ) 7.511.5 percent ( % ) Have type 1 diabetes mellitus ( T1DM ) , type diabetes mellitus apart T2DM Have know hypersensitivity allergy insulin , excipients contain insulin product , related compound Have use U500R within 3 month prior screen Have use rosiglitazone , pramlintide , weekly twice daily exenatide , injectable oral antihyperglycemic agent ( ) list inclusion criterion ; take oral antidiabetic medication dose exceed respective product label Have blood transfusion severe blood loss within 3 month prior screen know hemoglobinopathy , hemolytic anemia , sickle cell anemia may affect reliability HbA1c measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>